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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effectiveness of continuous versus intermittent antibiotics in the treatment of adults and children with bronchiectasis.
B A C K G R O U N D
Description of the condition
Bronchiectasis is a chronic airway disease characterised by abnor-
mal destruction and dilation of the large airways, bronchi and
bronchioles (Pasteur 2010). It is characterised radiologically by
permanent dilation of the bronchi, and clinically by a syndrome
of cough, sputum production and recurrent respiratory infections
(Chalmers 2014). The pathogenesis of bronchiectasis can be ex-
plained by the vicious cycle theory, whereby an initial insult to the
airway leads to bronchial wall inflammation and damage, and dis-
orderedmucociliary clearance, predisposing the patient to chronic
or recurrent infection resulting in further airway damage (Cole
1986; Chalmers 2013). An understanding of this cycle of persis-
tent bacterial colonisation, chronic inflammation of the bronchial
mucosa, and progressive tissue destruction is central to the man-
agement of bronchiectasis as strategies to arrest both inflamma-
tory and bacterial components are required to limit the progres-
sion of lung injury (Cole 1997; Pasteur 2010). Approximately half
of presenting cases are idiopathic, but the most common aetiol-
ogy is a previous chest infection, such as bacterial pneumonia or
tuberculosis (Pasteur 2010). Diagnosis is based on identification
of one or more abnormally dilated bronchi using high-resolution
computed tomography (HRCT) (Chang 2010; Pasteur 2010).
Bacteria most commonly isolated from the airways of patients
with bronchiectasis include non-typeableHaemophilus influenzae,
Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus
aureus and Moraxella catarrhalis (Foweraker 2011). Colonising
pathogens such as P aeruginosa, H influenzae and M catarrhalis
also commonly display antimicrobial resistance arising from in-
trinsic resistance mechanisms or frequent exposure to antimicro-
bial agents.
Approximately 29% to 70% of presenting cases are classified as
idiopathic. The most commonly assigned aetiology is post-infec-
tious bronchiectasis, a heterogenous group including patients with
childhood respiratory infections like pertussis, bacterial pneumo-
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nia or tuberculosis (Pasteur 2010). Diagnosis is based on identi-
fication of one or more abnormally dilated bronchi using HRCT
(Chang 2010; Pasteur 2010). The main aim of therapeutic man-
agement is reduction of symptoms, such as cough, breathlessness
and expectoration, reduction of the number and duration of ex-
acerbations and improvement in quality of life (Chalmers 2015;
Pasteur 2010).
Bronchiectasis was once considered a relatively rare disease but re-
cent studies have suggested an increasing prevalence, particularly
in those aged over 75 years (Weycker 2005), and higher prevalence
rates in low-income and middle-income countries (Habesoglu
2011). Globally, it is estimated that prevalence in adults will in-
crease from about 2.4 million in 2012 to over 3 million by 2020
(Polverino 2014). In the UK, point prevalence rates per 100,000
rose from 350.5 to 566.1 in women and from 301.2 to 485.5 in
men over a nine-year period, reflecting an increase of more than
60% and approximately 263,000 adults living with bronchiectasis
in 2013 (Quint 2016). Similarly, incidence rates per 100,000 per-
son-years over the same period rose from 21.2 to 35.2 in women
and from 18.2 to 26.9 in men, a 63% increase, with over 15,000
new cases in 2013. The prevalence per 10,000 across Europe
ranges from 6.6 in Germany to 7.9 in Sweden and 36.2 in Spain
(Miravitlles 2016; Ringshausen 2015).
The disease has a significant impact on children with worse qual-
ity of life in younger children and those with more frequent exac-
erbations (Kapur 2012). Bronchiectasis is also more common in
some indigenous groups where prevalence may be as high as 16
per 1000 among southwest Alaskan children and 15 per 1000 in
Australian Aboriginal and Torres Strait Islander children (Chang
2002). Furthermore, one study reported an incidence of 3.7 per
100,000 per year among New Zealand children aged under 15
years. This equates to an overall prevalence of 1 per 3000 children
and 1 per 625 Pacific children (Twiss 2005). It also demonstrates
that the incidence rate among children in New Zealand is almost
seven times higher than those from Finland (Twiss 2005).
An improvement in diagnosis resulting from easier access to high
quality CT scanners, and increased awareness of symptoms com-
mon to bronchiectasis and other lung diseases, have been cited as
factors contributing to increased prevalence (Goeminne 2016).
Non-cystic fibrosis (CF) bronchiectasis places an increasing
burden on healthcare systems internationally (Redondo 2016;
Chalmers 2015), with patients experiencing a high rate of exacer-
bations, hospital admissions and attributable mortality (Chalmers
2015). Patients colonised with P aeruginosa and those with a
more frequent annual exacerbation rate have an accelerated de-
cline in lung function, reduced health-related quality of life (mea-
sured using the St George’s Respiratory Questionnaire, SGRQ),
increased risk of hospitalisation and increasedmortality risk (Evans
1996; Martinez-Garcia 2007; Wilson 1997). A history of exacer-
bations, and particularly severe exacerbations, low body mass in-
dex, chronic bacterial infection, low forced expiratory volume in
one second (FEV )percentage predicted, a higher proportion of
affected lobes and more breathlessness are also associated with an
increased risk of hospitalisation and mortality (Chalmers 2014;
Rogers 2014; Seitz 2010). Average European mortality rates per
100,000 general population are estimated at 0.3 in 27 of the 28
European Union (EU) countries (ranging from 0.01 in Germany
to 1.18 in the UK) and 0.2 in nine non-EU countries (ranging
from 0.01 in Azerbaijan to 0.67 in Kyrgyzstan), based on 2005 to
2009 data (Gibson 2013). More recent UK figures estimate age-
adjusted mortality rates to be more than twice (2.26 in women,
2.14 in men) that of the general population (Quint 2016).
Bronchiectasis care is associated with substantial resource use. A
recent Spanish study reported a mean direct annual medical cost
for adult patients with bronchiectasis of EUR 4671, escalating
with disease severity (de la Rosa 2016). Furthermore, factors such
as FEV percentage predicted, age,Pseudomonas colonisation and
hospitalisation may independently influence health care costs. A
USA-based study reported an annual increase of USD 2319 in
overall costs and USD 1607 in respiratory-related costs in pa-
tients with bronchiectasis compared with matched case-controls,
attributed primarily to an increase of two outpatient visits and 1.6
respiratory-related visits per patient per year (Joish 2013).
Description of the intervention
Antibiotics, aiming to treat bacterial infections of the respiratory
tract, or to control bacterial colonisation, or both, represent a cen-
tral component of the treatment of non-CF bronchiectasis, as they
reduce bacterial load, inflammation and consequent tissue destruc-
tion in the airways (Chalmers 2012). Long-term prophylactic an-
tibiotics, administered for more than three months, have proved
effective for patients with frequent bronchiectasis exacerbations or
those with fewer exacerbations causing significant morbidity, as
they appear to decrease the frequency and severity of exacerbations,
at the expense of a significant increase in the risk of emerging drug
resistance (Hnin 2015). Patients taking continuous antibiotics are
more than three times at risk of bacterial resistance compared to
those who do not (Hnin 2015). Pathogens isolated in the sputum
cultures of these patients during an exacerbation or at stable dis-
ease, such as P aeruginosa, H influenzae or M catarrhalis commonly
display antimicrobial resistance arising from intrinsic resistance
mechanisms or frequent exposure to antimicrobial agents. There
is also risk of antibiotic-related adverse effects, such as hearing im-
pairment and cardiotoxicity (Serisier 2013).
Randomised controlled trials (RCTs) have evaluated different
modes of administration, namely oral, intravenous and inhaled,
and different classes of antibiotics including but not limited to
macrolides, quinolones or polymyxins. Two strategies for the ad-
ministration of long-term antibiotics have been described: (I) con-
tinuous and (ii) intermittent administration. In contrast to con-
tinuous, intermittent refers to the repeated prophylactic admin-
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istration of courses of antibiotics with predefined duration and
intervals. Examples include one short course of antibiotics every
month; month on and month off; or during the winter months.
This review will include intermittent antibiotic therapy where ad-
ministration is at predefined regular intervals over a duration of at
least three weeks, and where patients are not receiving concomi-
tant prophylactic antibiotics. We will compare continuous versus
intermittent administration of long-term prophylactic antibiotics
for at least three months.
How the intervention might work
There is a strong relationship between airway bacterial infec-
tion and disease morbidity in bronchiectasis for example, patients
chronically infected with P aeruginosa have a three-fold increase
in mortality, a 6.5 times increase in hospital admission rate and an
average of one additional exacerbation per patient per year, when
compared to patients not chronically infected with P aeruginosa
(Finch 2015). Other commonly isolated bacteria such as H in-
fluenzae andMcatarrhalis also drive an increase in neutrophilic in-
flammation (Chalmers 2012) and are associated with an increased
risk of severe exacerbations (Chalmers 2014). Antibiotic treatment
aims to suppress neutrophilic inflammation, reduce bacterial load
and thereby improve clinical outcomes (Brodt 2014). Continuous
administration of antibiotic treatment is based on the assumption
that chronic infection cannot be eradicated, and must therefore
be continuously suppressed to prevent a return of bacterial load,
increased inflammation and a recurrence of symptoms (Haworth
2014).
The principal of intermittent treatment is that with continuous
exposure to antibiotics, bacteria become resistant and treatment
may lose its effectiveness (Chalmers 2015). On the contrary, in-
termittent administration of antibiotics might remove or limit the
antibiotic selection pressure and, consequently, prevent the de-
velopment of resistance. While data are lacking on the impact
of intermittent versus continuous administration of antibiotics
on the development of antibiotic resistance among patients with
bronchiectasis, there is ample indirect evidence. Characteristically,
in a large retrospective analysis of mechanically-ventilated patients
with nosocomial infections, it was demonstrated that an interval
of at least 20 days between serial courses of antibiotics is associated
with a 24% reduction in development of resistance (Hui 2013).
An additional advantage of intermittent antibiotic administration
is a reduced treatment burden to patients and that continuous
administration may result in more side effects as a result of higher
cumulative exposure of the patient to antibiotics.
Why it is important to do this review
While long-term antibiotic treatments givenboth orally and via in-
halation are part of the standard care for patients with bronchiecta-
sis (Chalmers 2015), there is no agreement on the optimal method
of delivery of antibiotic therapies. It is common practice to ad-
minister both oral and inhaled antibiotics daily (Altenburg 2013;
Haworth 2014), on alternate days (Wong 2012), month on and
month off (Barker 2014) or during the winter months where pa-
tients may experience more exacerbations. International guide-
lines are unable to comment on which method of antibiotic ad-
ministration is most effective or is associated with the lowest rates
of adverse events or antibiotic resistance. A European Respiratory
Society/European Bronchiectasis Network (EMBARC) task force
produced 22 consensus recommendations for future research into
bronchiectasis, including “Studies should evaluate whether cyclic
or continuous administration of long-term antibiotics is superior
both in terms of clinical efficacy and the emergence of resistance”
(Aliberti 2016). As this was determined to be an important clinical
question by both patients and physicians, this systematic review
aims to evaluate the current evidence for continuous vs intermit-
tent administration of antibiotic treatment in bronchiectasis.
O B J E C T I V E S
To evaluate the effectiveness of continuous versus intermittent an-
tibiotics in the treatment of adults and children with bronchiec-
tasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) and cluster-
randomised trials . We will also include cross-over studies, but
will only use data from the first pre-cross-over phase to eliminate
potentially irreversible carry-over effects (e.g. antibiotic resistance).
We will include studies reported as full-text, those published as
abstract only, and unpublished data.
Types of participants
We will include adults and children (< 18 years) diagnosed with
bronchiectasis by bronchography, or computed tomography who
report daily signs or symptoms, such as cough, sputumproduction,
or those with recurrent episodes of chest infections. Studies will be
excluded if participants had received a diagnosis of cystic fibrosis
(CF) or active allergic bronchopulmonary aspergillosis. Data on
children and adults will be analysed separately.
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Types of interventions
Wewill compare continuous versus intermittent administration of
long-term prophylactic antibiotics of at least three months dura-
tion. The delivery method should be the same in all study groups,
e.g. nebulised versus nebulised, in order to isolate the effect of the
antibiotic rather than the delivery device.
We will consider intermittent administration of antibiotics, pro-
vided there are predefined regular intervals of antibiotic adminis-
tration followed by a duration of at least three weeks when partici-
pants do not receive prophylactic antibiotics (e.g. one short course
of antibiotics every month; month on and month off; or during
the winter months).
Types of outcome measures
Primary outcomes
1. Exacerbations (frequency, proportion with one or more,
duration, time to next exacerbation) (defined using study
authors’ criteria).
2. Antibiotic resistance, defined as either the presence of
antibiotic resistance after the administration of antibiotics for at
least three months, or the development of antibiotic resistance
within at least three months of antibiotic administration. We will
only evaluate resistance to the antibiotic(s) being investigated.
3. Serious adverse events.
Secondary outcomes
1. Health-related quality of life using measures validated in a
clinical setting (e.g. SGRQ, LCQ, QoL-B).
2. Hospital admissions due to exacerbations (frequency,
duration) (defined using study authors’ criteria).
3. Mortality (we will extract and report whether mortality is
defined as all-cause or bronchiectasis-related in the individual
studies).
4. Sputum volume and colour.
5. Symptoms (cough, dyspnoea, wheeze).
6. Lung function measured as forced expiratory volume in one
second (FEV ) (litres or percent of predicted).
7. Exercise capacity (e.g. 6MWD).
8. Adverse events/side effects.
We will use the definitions from Edwards 2000 and Hansen 2015
for serious adverse events and adverse events as follows:
1. Serious adverse events are those that result in death or life-
threatening events; requirement for hospitalisation or
prolongation of existing hospitalisation; persistent or significant
disability; or congenital anomalies, or are events that are
considered medically important.
2. Adverse events are any untoward occurrence that may
present while a patient is taking a drug but which does not
necessarily have a causal relation to the treatment. They are
undetectable by the patient; usually identified by laboratory tests
(e.g. biochemical, haematological, immunological, radiological,
pathological tests) or by clinical investigations (e.g. gastro-
intestinal endoscopy, cardiac catheterisation).
Reporting one or more of the outcomes listed here in the study is
not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
Wewill identify studies from theCochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources:
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org);
2. Weekly searches of MEDLINE Ovid SP 1946 to date;
3. Weekly searches of Embase Ovid SP 1974 to date;
4. Monthly searches of PsycINFO Ovid SP;
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature);
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine); and
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings, are in Appendix 1. See Appendix 2 for search terms used
to identify studies for this review.
We will search the following trials registries:
1. USA National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov)
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch)
Wewill search theCochrane Airways Trials Register and additional
sources from inception to present, with no restriction on language
of publication.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references.We will search relevant manufac-
turers’ websites for study information.
We will search for errata or retractions from included studies pub-
lished in full text on PubMed and report the date this was done
within the review.
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Data collection and analysis
Selection of studies
Two review authors (AM and TD) will screen the titles and ab-
stracts of the search results independently and code them as ’re-
trieve’ (eligible or potentially eligible/unclear) or ’do not retrieve’.
We will retrieve the full-text study reports of all potentially eligible
studies and two review authors (AM and TD) will independently
screen them for inclusion, recording the reasons for exclusion of
ineligible studies. We will resolve any disagreement through dis-
cussion or, if required, we will consult a review author (JC). We
will identify and exclude duplicates and collate multiple reports
of the same study so that each study, rather than each report, is
the unit of interest in the review. We will record the selection pro-
cess in sufficient detail to complete a PRISMA flow diagram and
’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in the
review. One review author (TD) will extract the following study
characteristics from included studies:
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
Two review authors (TD and LF) will independently extract out-
come data from included studies. We will note in the ’Characteris-
tics of included studies’ table if outcome data were not reported in
a usable way. We will resolve disagreements by consensus or by in-
volving a review author (JC). One review author (TD) will trans-
fer data into the ReviewManager file (ReviewManager 2014).We
will double-check that data are entered correctly by comparing the
data presented in the systematic review with the study reports. A
second review author (LF) will spot-check study characteristics for
accuracy against the study report.
Assessment of risk of bias in included studies
Two review authors (LF and TD) will assess risk of bias indepen-
dently for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (SM). We will assess the risk of bias according to
the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
We will judge each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgement in the ’Risk of bias’ table. We will sum-
marise the risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient-reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios, and continuous
data as mean differences or standardised mean differences.We will
enter data presented as a scale with a consistent direction of effect.
We will undertakemeta-analyses only when this is meaningful (i.e.
when treatments, participants and the underlying clinical question
are similar enough for pooling to make sense).
We will narratively describe skewed data reported as medians and
interquartile ranges.
When multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
same meta-analysis, we will halve the control group to avoid dou-
ble-counting.
Unit of analysis issues
In all included studies, the unit of analysis will be the participant.
In terms of exacerbation rates and hospitalisation rates, we plan
to focus on the number of events experienced by the participant
during the trial and to analyse the results using rate ratios if possi-
ble. We will use adjusted data if it is available (e.g. rate ratios from
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Poisson regression models, or mean differences from ANOVA or
results from cluster randomised studies adjusted for cluster effect)
as first choice, followed by change scores and final scores as last
choice.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as an abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will take this into consideration in
the GRADE rating for affected outcomes.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity
we will report it and explore the possible causes by prespecified
subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
We will conduct meta-analyses when the population, interven-
tions, outcomes and study designs are similar. In presence of sub-
stantial heterogeneity (> 50%), we will report outcomes in the
text, giving direction and size of the effect along with the strength
of the evidence (risk of bias). We envisage that antibiotic studies
will vary by population, design, and outcomes, therefore meta-
analysis using a random-effects model would be most appropriate.
However, where there are few studies or the effects of interven-
tions across studies are not randomly distributed (e.g. with pub-
lication bias), the estimates from a random-effects model may be
unreliable or biased. It is likely that this review will only include a
small number of low-powered studies, therefore wewill use a fixed-
effect model, reported with 95% confidence intervals (CI), and
evaluate the impact of model choice using a sensitivity analysis.
We will synthesise and report dichotomous and continuous data
separately for each outcome (e.g. exacerbation/no exacerbation or
exacerbation duration). Where end-of-study point estimates and
change from baseline scores are reported, we will analyse these
separately. Furthermore, we will use standardised mean difference
(SMD) when outcomes are measured using different scales (e.g.
health-related quality of life measures). We will also use standard
deviation (SD) of baseline for SMD analyses.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the follow-
ing outcomes: exacerbations, antibiotic resistance, serious adverse
events, hospitalisations, mortality, symptoms and quality of life.
We will use the five GRADE considerations (risk of bias, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of a body of evidence as it relates to the
studies that contribute data for the prespecified outcomes. We
will use the methods and recommendations described in Section
8.5 and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), using GRADEpro software
(GRADEpro GDT). We will justify all decisions to downgrade
the quality of studies using footnotes and we will make comments
to aid the reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses:
1. Mode of delivery (e.g. oral, nebulised).
2. Antibiotic class (e.g. macrolide).
3. Duration participants colonised with P aeruginosa.
4. Specifically for the outcome antibiotic resistance, we will
carry out subgroup analyses according to the definition of
antibiotic resistance (presence versus development of antibiotic
resistance after the administration of antibiotics for at least three
months).
We will use the following outcomes in subgroup analyses:
1. Exacerbations.
2. Antibiotic resistance.
3. Serious adverse events.
We will use the formal test for subgroup interactions in Review
Manager (Review Manager 2014).
Sensitivity analysis
We plan to evaluate the impact of methodological quality by using
the following domains to remove studies at high or unclear risk of
bias:
1. Random sequence generation.
2. Allocation concealment.
We will compare the results from a fixed-effect model with the
random-effects model.
A C K N OW L E D G E M E N T S
We would like to thank Edge Hill University for supporting this
study. We would also like to thank the Cochrane Airways Group
for its support.
Dr Chris Cates was the Editor for this review and commented
critically on the review.
6Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The Background and Methods sections of this protocol are based
on a standard template used by Cochrane Airways.
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure funding to Cochrane Air-
ways. The views and opinions expressed therein are those of the
authors and do not necessarily reflect those of the Systematic Re-
views Programme, NIHR, NHS or the Department of Health.
R E F E R E N C E S
Additional references
Aliberti 2016
Aliberti S, Masefield S, Polverino E, De Soyza A,
Loebinger MR, Menendez R, et al. Research priorities in
bronchiectasis: a consensus statement from the EMBARC
Clinical Research Collaboration. European Respiratory
Journal 2016;48(3):632–47. [PUBMED: 27288031]
Altenburg 2013
Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren
EH, Koppers RJ, et al. Effect of azithromycin maintenance
treatment on infectious exacerbations among patients with
non-cystic fibrosis bronchiectasis: the BAT randomized
controlled trial. JAMA 2013;309(12):1251–9. [PUBMED:
23532241]
Barker 2014
Barker AF, O’Donnell AE, Flume P, Thompson PJ, Ruzi
JD, de Gracia J, et al. Aztreonam for inhalation solution in
patients with non-cystic fibrosis bronchiectasis (AIR-BX1
and AIR-BX2): two randomised double-blind, placebo-
controlled phase 3 trials. Lancet 2014;2(9):738–49.
[PUBMED: 25154045]
Brodt 2014
Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for
stable non-cystic fibrosis bronchiectasis: a systematic
review. European Respiratory Journal 2014;44(2):382–93.
[PUBMED: 24925920]
Chalmers 2012
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan
JR, Hill AT. Short- and long-term antibiotic treatment
reduces airway and systemic inflammation in non-cystic
fibrosis bronchiectasis. American Journal of Respiratory and
Critical Care Medicine 2012;186(7):657–65. [PUBMED:
22744718]
Chalmers 2013
Chalmers JD, Hill AT. Mechanisms of immune
dysfunction and bacterial persistence in non-cystic fibrosis
bronchiectasis. Molecular Immunology 2013;55(1):27–34.
[PUBMED: 23088941]
Chalmers 2014
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ,
Lonni S, Davidson J, et al. The bronchiectasis severity
index. An international derivation and validation study.
American Journal of Respiratory and Critical Care Medicine
2014;189(5):576–85. [PUBMED: 24328736]
Chalmers 2015
Chalmers JD, Aliberti S, Blasi F. Management of
bronchiectasis in adults. European Respiratory Journal 2015;
45(5):1446–62. [PUBMED: 25792635]
Chang 2002
Chang AB, Grimwood K, Mulholland EK, Torzillo PJ.
Bronchiectasis in indigenous children in remote Australian
communities. Medical Journal of Australia 2002;177(4):
200–4. [PUBMED: 12175325]
Chang 2010
Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes
PW, King PT, et al. Chronic suppurative lung disease and
bronchiectasis in children and adults in Australia and New
Zealand. Medical Journal of Australia 2010;193(6):356–65.
[PUBMED: 20854242]
Cole 1986
Cole PJ. Inflammation: a two-edged sword - the model
of bronchiectasis. European Journal of Respiratory Diseases.
Supplement 1986;147:6–15. [PUBMED: 3533593]
Cole 1997
Cole P. The damaging role of bacteria in chronic lung
infection. Journal of Antimicrobial Chemotherapy 1997;40
Suppl A:5–10. [PUBMED: 9484867]
de la Rosa 2016
de la Rosa D, Martínez-García MA, Olveira C, Girón
R, Máiz L, Prados C. Annual direct medical costs of
bronchiectasis treatment: Impact of severity, exacerbations,
chronic bronchial colonization and chronic obstructive
pulmonary disease coexistence. Chronic Respiratory Disease
2016;13(4):361–71. [PUBMED: 27072020]
Edwards 2000
Edwards IR, Aronson JK. Adverse drug reactions:
definitions, diagnosis, and management. Lancet 2000;356
(9237):1255–9. [PUBMED: 11072960]
Evans 1996
Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead
MA. Lung function in bronchiectasis: the influence of
Pseudomonas aeruginosa. European Respiratory Journal
1996;9(8):1601–4. [PUBMED: 8866579]
7Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Finch 2015
Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S,
Chalmers JD. A comprehensive analysis of the impact of
Pseudomonas aeruginosa colonization on prognosis in adult
bronchiectasis. Annals of the American Thoracic Society
2015;12(11):1602–11. [PUBMED: 26356317]
Foweraker 2011
Foweraker J, Wat D.Microbiology of non-CF bronchiectasis
[Bronchiectasis]. In: Floto RA, Haworth CS editor(s).
European Respiratory Society Monographs. Vol. 52, European
Respiratory Society, 2011:68–96.
Gibson 2013
Gibson GJ, Loddenkemper R, Lundback B, Sibille Y.
Respiratory health and disease in Europe: the new European
Lung White Book. European Respiratory Journal 2013;
Vol. 42, issue 3:559–63. [PUBMED: 24000245]
Goeminne 2016
Goeminne PC, De Soyza A. Bronchiectasis: how to be an
orphan with many parents?. European Respiratory Journal
2016; Vol. 47, issue 1:10–3. [PUBMED: 26721955]
GRADEpro GDT [Computer program]
GRADE Working Group, McMaster University.
GRADEpro GDT. Version accessed 30 January 2017.
Hamilton (ON): GRADE Working Group, McMaster
University, 2014.
Habesoglu 2011
Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical,
radiologic, and functional evaluation of 304 patients with
bronchiectasis. Annals of Thoracic Medicine 2011;6(3):
131–6. [PUBMED: 21760844]
Hansen 2015
Hansen MP, Thorning S, Aronson JK, Beller EM, Glasziou
PP, Hoffmann TC, et al. Adverse events in patients taking
macrolide antibiotics versus placebo for any indication.
Cochrane Database of Systematic Reviews 2015, Issue 8.
[DOI: 10.1002/14651858.CD011825]
Haworth 2014
Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF,
Bilton D. Inhaled colistin in patients with bronchiectasis
and chronic Pseudomonas aeruginosa infection. American
Journal of Respiratory and Critical Care Medicine 2014;189
(8):975–82. [PUBMED: 24625200]
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Hnin 2015
Hnin K, Nguyen C, Carson KV, Evans DJ, Greenstone
M, Smith BJ. Prolonged antibiotics for non-cystic fibrosis
bronchiectasis in children and adults. Cochrane Database
of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/
14651858.CD001392.pub3]
Hui 2013
Hui C, Lin MC, Jao MS, Liu TC, Wu RG. Previous
antibiotic exposure and evolution of antibiotic resistance
in mechanically ventilated patients with nosocomial
infections. Journal of Critical Care 2013;28(5):728–34.
[DOI: 10.1016/j.jcrc.2013.04.008]
Joish 2013
Joish VN, Spilsbury-Cantalupo M, Operschall E, Luong
B, Boklage S. Economic burden of non-cystic fibrosis
bronchiectasis in the first year after diagnosis from a
US health plan perspective. Applied Health Economics
and Health Policy 2013;11(3):299–304. [PUBMED:
23580074]
Kapur 2012
Kapur N, Masters IB, Newcombe P, Chang AB. The burden
of disease in pediatric non-cystic fibrosis bronchiectasis.
Chest 2012;141(4):1018–24. [PUBMED: 21885727]
Martinez-Garcia 2007
Martínez-García MA, Soler-Cataluña JJ, Perpìñá-Tordera
M, Román-Sánchez P, Soriano J. Factors associated with
lung function decline in adult patients with stable non-
cystic fibrosis bronchiectasis. Chest 2007;132(5):1565–72.
[PUBMED: 17998359]
Miravitlles 2016
Miravitlles M, Monteagudo M, Rodríguez T, Barrecheguren
M, Simonet P, Sáez M, et al. Prevalence of bronchiectasis in
four European countries. Pneumologie 2016; Vol. 70, issue
1:A57.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman D. Preferred
reporting items for systematic reviews and meta-analyses:
the PRISMA statement. PLoS Medicine 2009;6(7):
e1000097. [DOI: 10.1371/journal.pmed.1000097]
Pasteur 2010
Pasteur MC, Bilton D, Hill AT, British Thoracic Society
Bronchiectasis (non-CF) Guideline Group. British Thoracic
Society Guidelines for non-CF bronchiectasis. Thorax
2010;65(Suppl1):i1-58.
Polverino 2014
Polverino E, Cacheris W, Spencer C, Operschall E, Donnell
AE. Global burden of non-cystic fibrosis bronchiectasis:
A simple epidemiological analysis. European Respiratory
Journal 2014;40(Suppl 56):P3983.
Quint 2016
Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL,
Hurst JR, et al. Changes in the incidence, prevalence and
mortality of bronchiectasis in the UK from 2004 to 2013: a
population-based cohort study. European Respiratory Journal
2016;47(1):186–93. [PUBMED: 26541539]
Redondo 2016
Redondo M, Keyt H, Dhar R, Chalmers JD. Global impact
of bronchiectasis and cystic fibrosis. Breathe 2016;12(3):
222–35.
8Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Review Manager 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Ringshausen 2015
Ringshausen FC, de Roux A, Diel R, Hohmann D,
Welte T, Rademacher J. Bronchiectasis in Germany:
a population-based estimation of disease prevalence.
European Respiratory Journal 2015; Vol. 46, issue 6:
1805–7. [PUBMED: 26293498]
Rogers 2014
Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC,
Rivett DW, et al. A novel microbiota stratification system
predicts future exacerbations in bronchiectasis. Annals
of the American Thoracic Society 2014;11(4):496–503.
[PUBMED: 24592925]
Seitz 2010
Seitz AE, Olivier KN, Steiner CA, Montes de Oca
R, Holland SM, Prevots DR. Trends and burden of
bronchiectasis-associated hospitalizations in the United
States, 1993-2006. Chest 2010;138(4):944–9. [PUBMED:
20435655]
Serisier 2013
Serisier DJ, Martin ML, McGuckin MA, Lourie R,
Chen AC, Brain B, et al. Effect of long-term, low-
dose erythromycin on pulmonary exacerbations among
patients with non-cystic fibrosis bronchiectasis: the BLESS
randomized controlled trial. JAMA 2013;309(12):1260–7.
[PUBMED: 23532242]
Twiss 2005
Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand
national incidence of bronchiectasis “too high” for a
developed country. Archives of Disease in Childhood 2005;
90(7):737–40. [PUBMED: 15871981]
Weycker 2005
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and
economic burden of bronchiectasis. Clinical Pulmonary
Medicine 2005;12(4):205–9.
Wilson 1997
Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ,
Wilson R. Effect of sputum bacteriology on the quality of
life of patients with bronchiectasis. European Respiratory
Journal 1997;10(8):1754–60. [PUBMED: 9272915]
Wong 2012
Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey
H, et al. Azithromycin for prevention of exacerbations
in non-cystic fibrosis bronchiectasis (EMBRACE): a
randomised, double-blind, placebo-controlled trial. Lancet
2012;380(9842):660–7. [PUBMED: 22901887]
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
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(Continued)
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify studies for the CAGR
Condition search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
10Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
16. or/1-15
17. exp Aspergillosis, Allergic Bronchopulmonary/
18. lung diseases, fungal/
19. aspergillosis/
20. 18 and 19
21. (bronchopulmonar$ adj3 aspergillosis).mp.
22. 17 or 20 or 21
23. 16 or 22
24. Lung Diseases, Obstructive/
25. exp Pulmonary Disease, Chronic Obstructive/
26. emphysema$.mp.
27. (chronic$ adj3 bronchiti$).mp.
28. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
29. COPD.mp.
30. COAD.mp.
31. COBD.mp.
32. AECB.mp.
33. or/24-32
34. exp Bronchiectasis/
35. bronchiect$.mp.
36. bronchoect$.mp.
37. kartagener$.mp.
38. (ciliary adj3 dyskinesia).mp.
39. (bronchial$ adj3 dilat$).mp.
40. or/34-39
41. exp Sleep Apnea Syndromes/
42. (sleep$ adj3 (apnea$ or apnoea$)).mp.
43. (hypopnoea$ or hypopnoea$).mp.
44. OSA.mp.
45. SHS.mp.
46. OSAHS.mp.
47. or/41-46
48. Lung Diseases, Interstitial/
49. Pulmonary Fibrosis/
50. Sarcoidosis, Pulmonary/
51. (interstitial$ adj3 (lung$ or disease$ or pneumon$)).mp.
52. ((pulmonary$ or lung$ or alveoli$) adj3 (fibros$ or fibrot$)).mp.
53. ((pulmonary$ or lung$) adj3 (sarcoid$ or granulom$)).mp.
54. or/48-53
55. 23 or 33 or 40 or 47 or 54
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
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11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify studies in other electronic databases
Appendix 2. Search strategy to identify relevant studies from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin or micin*
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectais]
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S O U R C E S O F S U P P O R T
Internal sources
• Edge Hill University, UK.
Funded Lambert Felix to provide support for a series of reviews on bronchiectasis.
External sources
• National Institute for Health Research (NIHR), UK.
Evidence to guide care in adults and children with asthma, 13/89/14
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